CMS
PAMA Reform Again a Top Lab Priority, but CBO Scoring, Congressional Chaos Add Complications
Premium
For the last six years Congress has passed delays to PAMA implementation, but such a pause could be less likely this year, warn industry stakeholders.
Texas Lab Executives Sentenced to Prison for Kickback Scheme
The former True Health Diagnostics executives were accused of participating in a scheme that paid Texas physicians for blood test referrals.
EntroGen Colorectal Cancer RAS Mutation Detection Test Nabs CMS Coverage
The real-time PCR-based companion diagnostic test identifies patients eligible for treatment with Amgen's Vectibix (panitumumab).
Interpace Diagnostics to Cease PancraGen Testing After Losing CMS Reimbursement
The fate of its pancreatic cancer test had been in limbo for years, but with a newly active LCD from Medicare contractor Novitas, the firm has had to close the book on the assay.
Medicare Covering BillionToOne Northstar Select Cancer Liquid Biopsy Test
The company's tumor genotyping test will now be reimbursed for eligible Medicare patients under Palmetto GBA's local coverage determination for this class of assays.